v3.26.1
Operating Segments - Schedule of Group’s CODM (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Schedule of Operating Segments [Line Items]      
External $ 856 $ 1,306 $ 2,879
Total 856 1,306 2,879
Cost of revenues 225 800 683
Research and development expenses 2,097 1,707 1,641
Sales and marketing 912 1,515 2,484
Impairment of intangible assets 115 1,344 1,042
General and administrative expenses 6,371 4,526 3,844
Other income, net (490) (1,270)
Segment loss (gain) 8,374 7,316 6,815
Equity losses from the investment in MitoCareX   429  
Company’s share of losses of company accounted for at equity, net 500 429 210
Gain from sale of an associate (2,231)
Finance expense (income), net 5,921 (259) (1,164)
Tax income (14) 22
Loss 12,564 7,472 5,883
Segment assets 7,622 10,171  
Segment liabilities 2,475 1,420  
Drug Development [Member]      
Schedule of Operating Segments [Line Items]      
External
Total
Cost of revenues
Research and development expenses 2,097 1,707 1,641
Sales and marketing
Impairment of intangible assets
General and administrative expenses 6,279 4,436 3,718
Other income, net (490) (1,270)
Segment loss (gain) 7,886 4,873 5,359
Segment assets 6,224 8,407  
Segment liabilities 2,213 1,194  
Online Sales [Member]      
Schedule of Operating Segments [Line Items]      
External 856 1,306 2,879
Total 856 1,306 2,879
Cost of revenues 225 800 683
Research and development expenses
Sales and marketing 912 1,515 2,484
Impairment of intangible assets 115 1,344 1,042
General and administrative expenses 92 90 126
Other income, net
Segment loss (gain) 488 2,443 $ 1,456
Segment assets 1,398 1,764  
Segment liabilities $ 262 $ 226